New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Bernhard T BauneDepartment of Psychiatry, School of Medicine, James Cook University, Queensland 4811, AustraliaAbstract: Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bernhard T Baune
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a35e124403f84828acb784b59cbbb6cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a35e124403f84828acb784b59cbbb6cc
record_format	dspace
spelling	oai:doaj.org-article:a35e124403f84828acb784b59cbbb6cc2021-12-02T03:08:09ZNew developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine1176-63281178-2021https://doaj.org/article/a35e124403f84828acb784b59cbbb6cc2008-10-01T00:00:00Zhttp://www.dovepress.com/new-developments-in-the-management-of-major-depressive-disorder-and-ge-a2328https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Bernhard T BauneDepartment of Psychiatry, School of Medicine, James Cook University, Queensland 4811, AustraliaAbstract: Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.Keywords: quetiapine, major depressive disorders, general anxiety disorder, randomized controlled studies, adverse effects Bernhard T BauneDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 6, Pp 1181-1192 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Bernhard T Baune New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
description	Bernhard T BauneDepartment of Psychiatry, School of Medicine, James Cook University, Queensland 4811, AustraliaAbstract: Quetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.Keywords: quetiapine, major depressive disorders, general anxiety disorder, randomized controlled studies, adverse effects
format	article
author	Bernhard T Baune
author_facet	Bernhard T Baune
author_sort	Bernhard T Baune
title	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
title_short	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
title_full	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
title_fullStr	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
title_full_unstemmed	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
title_sort	new developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a35e124403f84828acb784b59cbbb6cc
work_keys_str_mv	AT bernhardtbaune newdevelopmentsinthemanagementofmajordepressivedisorderandgeneralizedanxietydisorderroleofquetiapine
_version_	1718401936324034560

New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine

Ejemplares similares